UK Launches Large-Scale Clinical Trials of Medical Cannabis

Celadon Pharmaceuticals, a cannabis company, has launched full-scale clinical trials in the United Kingdom to test the therapeutic properties of cannabis on 5,000 patients.

People from Different Countries Can Participate

Last year, Celadon Pharmaceuticals completed a preliminary research phase involving 500 participants. The results showed that cannabis improved sleep quality and helped volunteers reduce their use of prescribed opioid painkillers. Based on these positive outcomes, UK authorities approved testing cannabis on a larger group of volunteers.

After receiving official approval, the company developed a research project and invested £4 million (about $5 million USD). The trials have recently begun and are expected to last two years. Residents of various countries who suffer from pain caused by any condition except cancer are eligible to participate. To try cannabis therapy, participants must:

• Fill out a form on the LVL Health clinic website;
• Upload photos of an ID document, a diagnosis certificate, and prescriptions for any medications prescribed by a doctor.

Volunteers will use cannabis packaged in cartridges with a RYAH vaporizer, which connects to a mobile app and collects real-time data on cannabinoid dosage. Doctors plan to analyze this data to determine whether cannabis improves patients’ quality of life, relieves pain, enhances sleep, and reduces the need for opioid painkillers.

RYAH Vaporizer

Celadon Pharmaceuticals Begins Supplying Medical Cannabis in the UK

Celadon Pharmaceuticals attracted £20 million (about $25 million USD) in investments to create a 0.9-hectare cannabis farm. The company has already completed two out of three indoor cultivation labs and harvested its first crop in the summer of 2022. In March 2023, Celadon became the first UK company licensed to sell cannabinoid-based medical products. With this license, the company began supplying medical cannabis to clinics.

Celadon Pharmaceuticals Cannabis Farm

Stock Market Performance

In 2018, the London Stock Exchange listed Celadon Pharmaceuticals’ shares. After receiving its license in March 2023, the company’s stock price tripled in just over a month. However, this upward trend quickly faded, and the share price gradually declined. Currently, the company’s shares are 41% below their April peak but remain 103% higher than at the start of the year.